Marex Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Marex Group’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,700	Closed	-$3.84K	–	886
2024 Q4	$3.84K	Buy	16,700 +4,000	+31%	+$4.8K	﹤0.01%	669
2024 Q3	$27.3K	Buy	+12,700	New	+$45.6K	﹤0.01%	575

Other funds holding SYRS

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Marex Group's SYRS Position: Q1 2025 in Review

Marex Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 16,700 shares — an estimated $3.84K sold.

Marex Group first reported a position in SYRS in Q3 2024 and held it in 2 quarters. The position peaked at $27.3K in Q3 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

Marex Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Marex Group sold 16,700 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $3.84K.
Marex Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
Marex Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $27.3K in Q3 2024.
7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Marex Group's 13F filing for Q1 2025, filed 2 Apr 2026.